Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1509567

Obinutuzumab-Induced Acute Thrombocytopenia: A Case Report and Literature Review

Provisionally accepted
Xuelin Dou Xuelin Dou 1Kongyang Li Kongyang Li 2Jin Lu Jin Lu 1*
  • 1 Peking University People's Hospital, Beijing, Beijing Municipality, China
  • 2 People's Hospital of Yangjiang, Yangjiang, Guangdong Province, China

The final, formatted version of the article will be published soon.

    Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is widely used in the treatment of B-cell lymphomas. Thrombocytopenia typically occurs 1 to 2 weeks after administration. In rare cases, obinutuzumab can induce severe acute thrombocytopenia within days of infusion, a condition known as "obinutuzumab-induced acute thrombocytopenia (OIAT)." Rituximab, a chimeric type I anti-CD20 monoclonal antibody, is also known to cause "rituximab-induced acute thrombocytopenia (RIAT)." This report presents a case of OIAT, with subsequent treatment switched to rituximab, which did not result in thrombocytopenia recurrence.

    Keywords: CD20 antibodies, lympho proliferative disorder, Adverse (side) effects, Obinutuzumab (GA101), acute thrombocytopenia

    Received: 11 Oct 2024; Accepted: 02 Dec 2024.

    Copyright: © 2024 Dou, Li and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jin Lu, Peking University People's Hospital, Beijing, 100044, Beijing Municipality, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.